Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects

Phase 1

Completed

Conditions: Benign Prostatic Hypertrophy (BPH)

Interventions: Drug: CKD-397

First Posted Date: 2015-11-26

Last Posted Date: 2017-08-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 16

Registration Number: NCT02615782

Locations: 🇰🇷
Dong-A University Hospital, Seo-gu, Busan, Korea, Republic of

Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients

Phase 4

Conditions: Hepatitis B, Chronic

Interventions: Drug: Baraclude Tab. 0.5mg
Drug: EntecaBell ODT. 0.5mg

First Posted Date: 2015-10-28

Last Posted Date: 2016-12-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 76

Registration Number: NCT02588937

Locations: 🇰🇷
Jeju National University Hospital, Jeju, Jeju-do, Korea, Republic of
🇰🇷
Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of
🇰🇷
Chonnam National University Hospital, Gwangju, Jeollanam-do, Korea, Republic of

and more 6 locations

Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet

Phase 1

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Viread® tablet
Drug: CKD-390

First Posted Date: 2015-10-28

Last Posted Date: 2016-01-12

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 40

Registration Number: NCT02589457

Locations: 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of

CKD-330 Phase 3 Trial in Amlodipine Non-responder

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: CKD-330 16/5mg
Drug: CKD-330 16/5mg Placebo
Drug: Amlodipine 5mg Placebo
Drug: Amlodipine 5mg

First Posted Date: 2015-10-26

Last Posted Date: 2016-10-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 160

Registration Number: NCT02586311

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg
Drug: CKD-395 0.5/1000mg

First Posted Date: 2015-10-01

Last Posted Date: 2015-10-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 26

Registration Number: NCT02565368

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of

Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-330 8/5mg
Drug: Candesartan 8mg
Drug: Amlodipine 5mg

First Posted Date: 2015-09-14

Last Posted Date: 2015-12-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 53

Registration Number: NCT02548286

Locations: 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of

Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled

Phase 4

Conditions: Hypertension

Interventions: Drug: Telminuvo®Tab. 40/2.5mg

First Posted Date: 2015-08-18

Last Posted Date: 2017-08-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 208

Registration Number: NCT02526875

Locations: 🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Gyeongsangbuk-do, Korea, Republic of
🇰🇷
Myongji Hospital, Goyang, Gyeonggi-di, Korea, Republic of
🇰🇷
Korean University Guro Hospital, Seoul, Guro-gu, Korea, Republic of

and more 7 locations

CKD-391 Pharmacokinetic Study Phase I

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CKD-391
Drug: Atrovastatin and Ezetimibe combination therapy

First Posted Date: 2015-07-17

Last Posted Date: 2016-12-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 46

Registration Number: NCT02501200

Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

Phase 3

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: CKD-342
Drug: Levocabastine HCL
Drug: Mometasone furoate

First Posted Date: 2015-07-15

Last Posted Date: 2016-12-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 459

Registration Number: NCT02498509

Locations: 🇰🇷
Samsung Medical Center, Irwon-dong, Gangnam-gu, Seoul, Korea, Republic of

Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: CKD-519 200mg / Fasting, Standard Meal, High Fat Meal

First Posted Date: 2015-06-29

Last Posted Date: 2015-12-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 45

Registration Number: NCT02484482

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy